Neuropati Diabetikum

01Pathophysiology

Diabetic neuropathy is the most common complication of diabetes and the most frequent cause of peripheral neuropathy worldwide. The underlying damage is driven by sustained hyperglycemia acting through several interconnected metabolic pathways.

The polyol (sorbitol) pathway is the most heavily tested mechanism. When intracellular glucose is elevated, the enzyme aldose reductase converts excess glucose into sorbitol, which cannot cross cell membranes efficiently. Sorbitol accumulates within Schwann cells and neurons, drawing water in by osmotic force and causing cellular swelling and dysfunction. Sorbitol is then slowly oxidized to fructose, depleting NADPH in the process. Because NADPH is required to regenerate glutathione (the cell's primary antioxidant), its depletion leaves the nerve vulnerable to oxidative stress.

Simultaneously, chronic hyperglycemia promotes the non-enzymatic glycosylation of structural proteins, forming advanced glycation end products (AGEs). AGEs bind to receptors on endothelial cells and macrophages, triggering inflammatory cascades and thickening the basement membrane of the vasa nervorum (the tiny blood vessels supplying peripheral nerves). This microvascular ischemia compounds the direct metabolic injury, starving the nerve of oxygen and nutrients.

The result is a length-dependent axonal degeneration: the longest nerve fibers are affected first because they are furthest from the cell body and most metabolically vulnerable. This is why symptoms begin at the toes and feet and gradually ascend. Small unmyelinated C fibers (carrying pain and temperature) are damaged early, producing burning pain and dysesthesias. As the disease progresses, large myelinated fibers (carrying vibration and proprioception) are lost, resulting in numbness, gait imbalance, and loss of protective sensation. The "stocking-glove" pattern directly reflects this length-dependent process: once symptoms reach the mid-calf, the fingertips begin to be involved because those are the next-longest fibers.

Autonomic nerve fibers are also susceptible, leading to a parallel syndrome of cardiovascular (resting tachycardia, orthostatic hypotension), gastrointestinal (gastroparesis), genitourinary (erectile dysfunction, neurogenic bladder), and sudomotor (anhidrosis) dysfunction.

02Classification and Clinical Manifestation

03Diagnostic Workup

Diabetic neuropathy is fundamentally a clinical diagnosis. In a patient with established diabetes, a symmetric stocking-glove pattern of sensory loss, and an abnormal monofilament or tuning fork exam, no further testing is needed to confirm the diagnosis. This is the scenario most commonly tested on exams: recognize the pattern and move straight to management.

However, the exam will also test your ability to exclude other causes of neuropathy, especially when the presentation is atypical. Red flags that should prompt further investigation include: predominantly motor symptoms, rapid onset, marked asymmetry, onset within five years of a Type 1 diabetes diagnosis, or progression despite adequate glycemic control. In these situations, order serum B12 (to rule out deficiency, which also causes a length-dependent neuropathy), TSH (hypothyroid neuropathy), and serum protein electrophoresis (SPEP) (to screen for paraproteinemia and amyloidosis).

Nerve conduction studies (NCS) and electromyography (EMG) are reserved for cases where the diagnosis is genuinely unclear or the pattern does not fit diabetic neuropathy. NCS will reveal an axonal pattern (reduced amplitudes with relatively preserved conduction velocity), which distinguishes it from demyelinating conditions like Guillain-Barre syndrome or CIDP, where conduction velocity is prominently reduced.

For patients presenting with isolated burning pain and normal NCS (suggesting small-fiber neuropathy), a skin punch biopsy measuring intraepidermal nerve fiber density is the gold standard. This is a growing testing point as small-fiber neuropathy becomes better recognized.

Autonomic neuropathy is confirmed with cardiovascular autonomic reflex tests: heart rate variability during deep breathing, the Valsalva ratio, and orthostatic blood pressure measurements. Gastric scintigraphy (the four-hour solid-meal study) is the standard for confirming gastroparesis.

04Management and Treatment

The single most important intervention tested on licensing exams is glycemic control. Tight glucose management (HbA1c below 7%) has been shown in landmark trials to reduce the incidence and progression of diabetic neuropathy. In Type 1 diabetes, the benefit is robust. In Type 2 diabetes, the evidence for reversal is weaker, but glycemic control remains the cornerstone because no other intervention addresses the underlying cause.

For symptomatic neuropathic pain, pregabalin and duloxetine carry the strongest evidence and are the most commonly tested first-line choices. A vignette presenting a diabetic patient with burning foot pain and asking for the "next best step in management" after glycemic optimization is almost always pointing toward one of these two agents. The choice between them is guided by comorbidities: duloxetine is preferred in a patient with coexisting depression or anxiety; pregabalin is preferred when the patient has concurrent generalized anxiety or insomnia (it causes somnolence). In renal impairment, pregabalin and gabapentin both require dose reduction.

Tricyclic antidepressants are effective but carry a higher side-effect burden. They are contraindicated in patients with cardiac arrhythmias or recent myocardial infarction due to their pro-arrhythmic and anticholinergic effects. This is a frequent exam distractor: a vignette may describe an elderly diabetic with neuropathic pain and a prolonged QT interval, where amitriptyline would be the wrong answer.

Opioids are explicitly discouraged for chronic diabetic neuropathic pain and should not be selected as a correct answer on the exam except in refractory, supervised, short-term contexts. Tramadol and tapentadol may appear as later-line options.

For gastroparesis, the tested drug is metoclopramide, a dopamine antagonist and prokinetic. The critical pearl is the risk of tardive dyskinesia with prolonged use, which limits the recommended duration to 12 weeks. If a vignette mentions a diabetic patient on metoclopramide who develops involuntary facial movements, the answer is to discontinue the drug.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on diabetic neuropathy questions is by failing to recognize atypical presentations that point away from simple DSPN. A vignette describing asymmetric proximal leg weakness and thigh pain in a diabetic patient is not "regular diabetic neuropathy." That is diabetic amyotrophy, and selecting "distal symmetric polyneuropathy" would be incorrect. Similarly, an acute CN III palsy with a spared pupil in a diabetic patient should immediately signal diabetic mononeuropathy, not a posterior communicating artery aneurysm (which causes CN III palsy with a fixed, dilated pupil because the parasympathetic fibers run on the outside of the nerve and are compressed first by the aneurysm).

Another classic trap involves the workup. When the vignette gives you a straightforward diabetic patient with symmetric stocking-glove numbness, the answer is almost never "order nerve conduction studies." The diagnosis is clinical. But when the vignette introduces a red flag (rapid progression, asymmetry, motor predominance, or very early onset in a young Type 1 patient), you must recognize that further workup is warranted. The exam is testing whether you can distinguish "classic presentation, treat it" from "atypical presentation, investigate further."

On the treatment side, the most heavily tested trap involves amitriptyline in the elderly or in patients with cardiac disease. A vignette pairing neuropathic pain with urinary retention, constipation, or a cardiac conduction abnormality is begging you to avoid the TCA and choose pregabalin or duloxetine instead. Watch for the combination of diabetes, neuropathy, and a prolonged QTc on ECG: that patient should receive duloxetine or pregabalin, not amitriptyline.

Finally, remember that foot care is a cornerstone of management that gets tested indirectly. A diabetic patient with neuropathy who presents with a painless ulcer on the plantar surface of the foot is the classic setup for a question about loss of protective sensation. The patient did not feel the injury because of the neuropathy. The "most important next step" in preventing recurrence is monofilament-based screening and a structured foot care program, not simply adding another pain medication.

The core competency being tested across all diabetic neuropathy questions is your ability to connect the pathophysiology (length-dependent axonal damage from hyperglycemia) to the clinical pattern (distal-to-proximal, sensory-first, symmetric), and then to apply the correct diagnostic and treatment sequence based on whether the case is classic or atypical.